Neuroscience
Odor identification deficits identify Parkinson's disease patients with poor cognitive performance
Movement Disorders. 2011 Sep;26(11):2045-50
Damholdt MF, Borghammer P, Larsen L, Ostergaard K
Abstract
Olfactory dysfunction is a prodromal and prevalent nonmotor symptom of Parkinson's disease. Unlike olfactory dysfunction in Alzheimer's disease, it is believed to be unrelated to cognitive impairment. However, recent research has implicated cholinergic denervation in Parkinson's disease hyposmia and linked it to verbal memory. This research hypothesized that severe odor identification deficits may identify patients with Parkinson's disease at risk for cognitive impairment. The current study tested this hypothesis by comparing 24 functionally anosmic, nondemented patients with Parkinson's disease and 39 nonanosmic, nondemented patients with Parkinson's disease with 29 healthy control participants on composite scores of memory, processing speed, executive function, and language. The functionally anosmic group had significantly poorer visual and verbal memory than the nonanosmic group, which was indistinguishable from the control group. Furthermore, the functionally anosmic group had reduced processing speed compared with the nonanosmic patients with Parkinson's disease, who, in turn, were outperformed by the control group. On the composite language score, the score of the functionally anosmic group was significantly reduced compared with that of the control group, whereas the nonanosmic group scored in the medium range. The 2 patient groups did not differ on executive functioning. These findings demonstrate co-occurrence between reduced cognitive function and olfactory deficits in functionally anosmic patients with Parkinson's disease and support the notion of more severe cognitive deficits in this group.
PMID: 21638326 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Parkinson's Disease
Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, & Gironell A. Parkinson's disease-cognitive rating scale: A new cognitive scale specific for Parkinson's disease. Movement Disorders. 2008 Mar 31 [Epub ahead of print]....
- Neuropsychology Abstract Of The Day: Chronic Congestive Heart Failure And Neuropsychological Function
Vogels RL, Oosterman JM, van Harten B, Scheltens P, van der Flier WM, Schroeder-Tanka JM, & Weinstein HC. Profile of Cognitive Impairment in Chronic Heart Failure. Journal of the American Geriatrics Society. 2007 Aug 28; [Epub ahead of print]. Department...
- Neuropsychology Abstract Of The Day: Olfactory Functioning And Mild Cognitive Impairment (mci)
Djordjevic J, Jones-Gotman M, De Sousa K, & Chertkow H. (2007). Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiology and Aging [epub ahead of print.] Montreal Neurological Institute, 3801 University Street, Department...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...
Neuroscience
Neuropsychology Abstract of the Day: Parkinson's and Anosmia
Odor identification deficits identify Parkinson's disease patients with poor cognitive performance
Movement Disorders. 2011 Sep;26(11):2045-50
Damholdt MF, Borghammer P, Larsen L, Ostergaard K
Abstract
Olfactory dysfunction is a prodromal and prevalent nonmotor symptom of Parkinson's disease. Unlike olfactory dysfunction in Alzheimer's disease, it is believed to be unrelated to cognitive impairment. However, recent research has implicated cholinergic denervation in Parkinson's disease hyposmia and linked it to verbal memory. This research hypothesized that severe odor identification deficits may identify patients with Parkinson's disease at risk for cognitive impairment. The current study tested this hypothesis by comparing 24 functionally anosmic, nondemented patients with Parkinson's disease and 39 nonanosmic, nondemented patients with Parkinson's disease with 29 healthy control participants on composite scores of memory, processing speed, executive function, and language. The functionally anosmic group had significantly poorer visual and verbal memory than the nonanosmic group, which was indistinguishable from the control group. Furthermore, the functionally anosmic group had reduced processing speed compared with the nonanosmic patients with Parkinson's disease, who, in turn, were outperformed by the control group. On the composite language score, the score of the functionally anosmic group was significantly reduced compared with that of the control group, whereas the nonanosmic group scored in the medium range. The 2 patient groups did not differ on executive functioning. These findings demonstrate co-occurrence between reduced cognitive function and olfactory deficits in functionally anosmic patients with Parkinson's disease and support the notion of more severe cognitive deficits in this group.
PMID: 21638326 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Parkinson's Disease
Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, & Gironell A. Parkinson's disease-cognitive rating scale: A new cognitive scale specific for Parkinson's disease. Movement Disorders. 2008 Mar 31 [Epub ahead of print]....
- Neuropsychology Abstract Of The Day: Chronic Congestive Heart Failure And Neuropsychological Function
Vogels RL, Oosterman JM, van Harten B, Scheltens P, van der Flier WM, Schroeder-Tanka JM, & Weinstein HC. Profile of Cognitive Impairment in Chronic Heart Failure. Journal of the American Geriatrics Society. 2007 Aug 28; [Epub ahead of print]. Department...
- Neuropsychology Abstract Of The Day: Olfactory Functioning And Mild Cognitive Impairment (mci)
Djordjevic J, Jones-Gotman M, De Sousa K, & Chertkow H. (2007). Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiology and Aging [epub ahead of print.] Montreal Neurological Institute, 3801 University Street, Department...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...